BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China

The facility's design incorporates environmental protection, energy conservation, emission reduction, and resource utilization – a reflection of WuXi...

October 26, 2022 | News

WuXi Biologics adds further capacity and capability for drug product fill & finish

WuXi Biologics to provide global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP. WuXi Biologics ("WuXi Bio"...

October 24, 2022 | News

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft

GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and GeneCraft (Suk Chul Bae, CEO), a global research team led by Professor Suk Ch...

October 18, 2022 | News

Samsung Biologics obtains three global ISO certifications

Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems F...

October 14, 2022 | News

Samsung Biologics unlocks additional capacity for production at its newest Plant 4

Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned Partial operations add fresh biomanufacturing capacity of 60,000...

October 12, 2022 | News

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

Within the partnership, Toregem BioPharma will have access to WuXi Biologics' integrated CMC services in cell line development, cell banking and testing se...

October 12, 2022 | News

Vetter drives its sustainability campaign forward

Repeat participation in Baden Wuerttemberg’s Sustainability Days Greater inclusion of employees due to involvement in various initiatives Awards ...

October 11, 2022 | News

Australia's Paradigm Biopharmaceuticals reports positive early osteoarthritis drug trial results

Australian repurposing drug company Paradigm Biopharmaceuticals says positive clinical trial results for its osteoarthritis drug candidate indicate a poten...

October 07, 2022 | News

Merck Boosts Commercial Capacity in France as Part of New Millipore® CTDMO Services

New 2,700-square-meter facility expands production capacity for monoclonal antibodies (mAbs) and other recombinant proteins Clients benefit from differe...

October 05, 2022 | News

Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™

Two distinctive platforms will streamline the antibody development process. With an advanced design and high binding affinity, S-DUAL™ ensures opt...

September 30, 2022 | News

Emmes (CRO) Acquires Clinical Edge

- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical in...

September 30, 2022 | News

WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

WuXi STA, a leading global Contract Research Development and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP)...

September 27, 2022 | News

GMP cell CDMO I Peace, Inc. in collaboration with universities successfully converted human dermal fibroblasts into oligodendrocyte by direct reprogramming

This research was jointly conducted with Prof. Wernig at Sanford University and Prof. Rowitch at UCSF. The research was published in the online edition of ...

September 21, 2022 | News

Rapid growth puts Australian CRO Accelagen on the map for clinical research globally

Accelagen, one of Australia's leading Contract Research Organisations, has taken new 472sqM office space in Hawthorn East following two year...

September 20, 2022 | News

Stay Connected